Guardant Health Stock Price, News & Analysis

Guardant Health (Nasdaq: GH) announced its Shield™ multi-cancer detection (MCD) test has been selected by the National Cancer Institute (NCI) for inclusion in the Vanguard study. The selection was based on the platform's strong performance in detecting various cancer types and predicting cancer tissue origin.

The Vanguard study is a four-year pilot initiative by the NCI's Cancer Screening Research Network (CSRN) that will enroll up to 24,000 people to inform the design of a larger randomized controlled trial evaluating MCD tests for cancer screening. Guardant Health was chosen as one of only two participants after evaluation of multiple companies.

The study will assess the Shield platform's performance in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric cancers. Results from the NCI verification study are expected in early 2025.

Guardant Health (Nasdaq: GH), a leading precision oncology company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management team will deliver a presentation followed by a Q&A session on Monday, January 13, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time.

Interested investors and stakeholders can access both live and archived webcasts of the sessions through the 'Investors' section of Guardant Health's official website at www.guardanthealth.com.

Guardant Health (Nasdaq: GH) and Meaningful Insights Biotech Analytics (MiBA) have announced a strategic partnership to enhance precision oncology through biomarker testing and data analytics. The collaboration combines MiBA's AI technologies and oncology data with Guardant's expertise in tumor profiling and circulating tumor DNA monitoring.

The partnership aims to transform cancer care by implementing personalized, data-driven approaches that improve access to innovative treatments. The initiative will provide healthcare stakeholders with knowledge about biomarker testing, cancer recurrence monitoring tools, and data insights throughout the care continuum, ultimately improving cancer patient care standards.

COTA and Guardant Health (Nasdaq: GH) announced a partnership to combine their oncology data resources for advancing precision cancer therapy development. The collaboration merges COTA's research-grade EHR data from academic and community care centers with Guardant's clinicogenomic testing data.

This partnership aims to help researchers better understand correlations between molecular biomarkers, treatments, and clinical outcomes. The combined dataset and AI analytics will support more efficient drug development, particularly given that 97% of cancer clinical trials fail and development can take up to fifteen years.

The collaboration expands COTA's data breadth into solid tumors, focusing on lung, breast, and colorectal cancers. Guardant's data covers all disease stages, from initial tumor profiling to therapy monitoring, while COTA's data tracks complete cancer care journeys.

Guardant Health (Nasdaq: GH) announced a collaboration with Boehringer Ingelheim to develop the Guardant360® CDx liquid biopsy as a companion diagnostic for zongertinib, an investigational treatment for non-small cell lung cancer (NSCLC). The blood test will identify NSCLC patients with HER2 mutations who may benefit from zongertinib treatment.

According to Guardant Health's chairman, approximately 40,000 people worldwide are diagnosed annually with NSCLC with HER2 mutations, who often respond poorly to standard treatments. The Guardant360 CDx is already FDA-approved for comprehensive liquid biopsy in advanced solid tumors and serves as a companion diagnostic for multiple NSCLC targeted therapies and breast cancer therapy targeting ESR1 mutations.

Guardant Health (Nasdaq: GH) announced upcoming presentations at the San Antonio Breast Cancer Symposium (SABCS) 2024, showcasing research on their liquid biopsy tests and AI analytics. The company will present eight posters, including a spotlight presentation on the Guardant Reveal test, which investigates circulating tumor DNA (ctDNA) dynamics in breast cancer treatment.

The research suggests that ctDNA analysis could help predict endocrine therapy sensitivity and long-term outcomes in HR+ breast cancer. The presentations will cover various topics including molecular profiling, minimal residual disease testing, and real-world data analysis using Guardant's products such as GuardantINFORM, Guardant Infinity, Guardant360 CDx, and Guardant Reveal.

A federal court jury unanimously ruled in favor of Guardant Health in its lawsuit against Natera for false advertising and unfair competition. The jury awarded $292.5 million to Guardant Health, including $175.5 million in punitive damages, making it one of the largest false advertising verdicts in history. The case, filed in May 2021, centered on Natera's deliberate campaign to mislead cancer clinicians about Guardant Reveal™, a tissue-free minimal residual disease test for early-stage colorectal cancer. The jury rejected all of Natera's counterclaims.

Guardant Health (Nasdaq: GH) announced the approval of equity grants to new non-executive employees under its 2023 Employment Inducement Incentive Award Plan. The grants include 233,603 restricted stock units (RSUs) to 123 employees and stock options to purchase 50,349 shares to three employees. The RSUs vest annually over three years, while the stock options, priced at $28.16 per share, vest one-third after one year and monthly thereafter over 24 months. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.

Guardant Health (GH) reported strong Q3 2024 financial results with revenue of $191.5 million, marking a 34% increase year-over-year. The company performed 53,100 clinical tests and 10,500 biopharma tests, up 21% and 40% respectively. Key highlights include achieving a Guardant360 ASP over $3,000 and receiving favorable Medicare pricing of $920 for Shield. The company raised its 2024 revenue guidance to $720-725 million, representing 28-29% growth. Free cash flow improved to $(55) million from $(80) million in the prior year. Despite revenue growth, the company reported a net loss of $107.8 million for Q3 2024.